Savara Inc. (NASDAQ:SVRA) Stock Has Consensus Price Target of $10.25 According to Brokerages

Savara Inc. (NASDAQ:SVRA) has been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $10.25.

SVRA has been the topic of several research reports. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. started coverage on Savara in a research report on Wednesday, October 7th. They set an “overweight” rating and a $12.00 price target for the company. Royal Bank Of Canada set a $10.00 price target on Savara in a research note on Wednesday, October 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Friday, July 17th. Finally, Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a report on Sunday, October 4th.

Institutional Trading of Savara

A number of institutional investors have recently modified their holdings of SVRA. BlackRock Inc. purchased a new position in Savara in the second quarter valued at approximately $76,966,000. Polar Capital Holdings Plc acquired a new position in Savara during the fourth quarter valued at approximately $50,086,000. Nantahala Capital Management LLC acquired a new position in Savara during the second quarter valued at approximately $42,977,150. Spruce Street Capital LP acquired a new position in Savara during the second quarter valued at approximately $21,267,868. Finally, Pictet Asset Management Holding SA purchased a new stake in Savara during the first quarter worth approximately $12,424,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Trading Down 0.4%

NASDAQ:SVRA opened at $4.74 on Tuesday. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara has a fifty-two week low of $3.49 and a fifty-two week high of $7.01. The firm’s 50 day moving average is $5.26 and its two-hundred day moving average is $5.40.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). On average, equities research analysts predict that Savara will post -0.66 earnings per share for the current fiscal year.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled formulation of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for autoimmune pulmonary alveolar proteinosis (aPAP), a rare disorder in which surfactant accumulates in the lungs and impairs breathing.

Savara has conducted clinical development activities in the United States and internationally, including Europe.